Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioVex Group, Inc.
Woburn, Massachusetts, United Statesbiovex.com ↗
- Ownership
- Private
- Employees
- ~66
- Development stage
- Other
01
Overview
BioVex developed OncoVEX(GM-CSF), an investigational oncolytic vaccine that reached Phase 3 clinical development for treating melanoma and head and neck cancer. The company was acquired by Amgen in March 2011, and its lead product (later known as T-Vec or talimogene laherparepvec) received FDA approval on October 27, 2015.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Biologicsoncolytic viruses
- Industry
- Biotech
Beyond the preview
Go deeper on BioVex Group, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioVex Group, Inc..